Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00499603
First received: July 9, 2007
Last updated: August 27, 2013
Last verified: August 2013
  Purpose

The goal of this clinical research is to learn if RAD001 given in combination with chemotherapy will turn off the signaling pathway (a chain of information that tells cancer cells to grow quickly) and make the chemotherapies given on this study more effective.

Primary Objective

· To determine if the addition of an mTOR inhibitor to standard neoadjuvant chemotherapy in patients with triple receptor-negative breast cancer causes molecular changes (inhibition/activation) of the PI3K/PTEN/AKT pathway.

Secondary Objectives

  • To evaluate pathologic complete response (pCR) rates for each treatment group.
  • To evaluate the relationship between pCR and the molecular changes (inhibition/activation) of the PI13K/PTEN/AKT pathway in each treatment group.
  • To evaluate overall response rates (ORR) for each treatment group.
  • To assess the toxicity of both regimens and to evaluate the relationship of toxicities with PI3K/PTEN/AKT pathway status.

Condition Intervention Phase
Breast Cancer
Drug: Paclitaxel
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: RAD001
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101)

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Number Participants With Inhibition of PI3K/PTEN/AKT Pathway at 48 Hours [ Time Frame: 48 hours after start of treatment ] [ Designated as safety issue: No ]
    Number of participants with inhibition of the PI3K/PTEN/AKT pathway at 48 hours after the start of treatment, regardless of the status of the pathway at the time of randomization. Molecular changes (inhibition/activation) of the PI3K/PTEN/AKT pathway evaluated using reverse phase protein arrays (RPPA) where fine-needle aspirations (FNAs) from the primary breast cancer obtained pretreatment, and at 48 hours. Bioinformatics cluster analysis of arrays used to define molecular changes as inhibition or activation where pathways called 'active' with presence of 2 or more phosphorilated pathway proteins (pAKT, pmTOR, pGSK3, pS6K1, pS6), and 'inhibited' with one or none phosphorilated pathway proteins present.


Secondary Outcome Measures:
  • Participant Responses Per Treatment Arm at 12 Weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Radiographic criteria of response based on regional ultrasound examination (decrease in size of the primary tumor and/or fatty replacement in regional lymph nodes), and includes partial response and complete response. A decrease in size of the product of the two largest dimensions =/> 50% considered a partial response (PR), and a complete disappearance of the primary tumor by physical exam and or ultrasound and normalization of the lymph nodes by ultrasound will be considered a complete clinical response (CR). Stable Disease (SD) is carcinoma neither decreasing nor increasing in extent or severity, and Progression of disease (PD) defined as 30% increase in size primary tumor and/or lymph nodes on physical exam and/or ultrasound.

  • Participant Responses Per Treatment Arm at 24 Weeks [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    Radiographic criteria of response based on regional ultrasound examination (decrease in size of the primary tumor and/or fatty replacement in regional lymph nodes), and includes partial response and complete response. A decrease in size of the product of the two largest dimensions =/> 50% considered a partial response (PR), and a complete disappearance of the primary tumor by physical exam and or ultrasound and normalization of the lymph nodes by ultrasound will be considered a complete clinical response (CR). Stable Disease (SD) is carcinoma neither decreasing nor increasing in extent or severity, and Progression of disease (PD) defined as 30% increase in size primary tumor and/or lymph nodes on physical exam and/or ultrasound.


Enrollment: 62
Study Start Date: July 2007
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Paclitaxel + FEC
Paclitaxel 80 mg/m^2 intravenously (IV) on day 1(+/- 2 days) of each week, followed by four cycles of combination 5-Fluorouracil at 500 mg/m^2, Epirubicin at 100 mg/m^2 and Cyclophosphamide at 500 mg/m^2 (FEC) on day 1 every 3 weeks (+/- 7 days).
Drug: Paclitaxel
80 mg/m^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
Other Name: Taxol
Drug: 5-Fluorouracil
500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Other Names:
  • 5-FU
  • Adrucil
  • Efudex
Drug: Epirubicin
100 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Drug: Cyclophosphamide
500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Other Names:
  • Cytoxan®
  • Neosar®
Experimental: Paclitaxel + RAD001 + FEC
Paclitaxel + RAD001 Followed by FEC (5-Fluorouracil + Epirubicin + Cyclophosphamide)
Drug: Paclitaxel
80 mg/m^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
Other Name: Taxol
Drug: 5-Fluorouracil
500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Other Names:
  • 5-FU
  • Adrucil
  • Efudex
Drug: Epirubicin
100 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Drug: Cyclophosphamide
500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Other Names:
  • Cytoxan®
  • Neosar®
Drug: RAD001
30 mg by mouth weekly on Days 1, 8, & 15 for 12 cycles.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with histologic confirmation of invasive ER/PR and HER2/neu-negative breast carcinoma. Immunohistochemistry (IHC) must be used for ER/PR evaluation and IHC or FISH for determination of HER2/neu. ER/PR will be considered negative if equal or lower than 5% IHC staining and HER2/neu will be considered negative if IHC of 0% or negative FISH.
  2. Patients must have intact primary tumors.
  3. Age equal or greater than 18 years
  4. Patients should have stage IIA (T1N1) to IIIC non inflammatory breast cancer.
  5. Patients with bilateral breast cancers are eligible.
  6. Patients should have a Karnofsky performance scale of =/> 70%.
  7. Patients must have clinically measurable disease to be treated in the neoadjuvant setting. This includes patients with a non-palpable primary tumor who have histologically proven lymph node involvement that is clinically palpable and measurable by ultrasound.
  8. Patients should have adequate bone marrow function, as defined by peripheral granulocyte count of >/= 1500/mm3, and a platelet count >/= 100000/ mm3.
  9. Patients must have adequate liver function with a bilirubin within normal laboratory values. Alkaline phosphatase and transaminases (ALT and AST) may be up to 1.5 x upper limit of normal (ULN) of the institution.
  10. Patients should have adequate renal function with creatinine levels 2.0 mg/dL or lower
  11. Patients should have a normal left ventricular ejection fraction of =/> 50%.
  12. Negative serum pregnancy test for a woman of childbearing potential.
  13. Women of childbearing potential (WOCBP) must use a reliable and appropriate contraceptive method during the study and 6 months after chemotherapy is completed. WOCBP are women who are not menopausal for 12 months or had no previous surgical sterilization.
  14. Patients must agree to have study biopsies.
  15. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.
  16. Hemoglobin 9.0 gm/dL or higher

Exclusion Criteria:

  1. Patients whose tumors express ER, PR or HER2/neu gene amplification.
  2. Patients with a history of other invasive malignancies diagnosed and treated within the previous 5 years, except non-melanoma skin cancer and non-invasive cervical cancer
  3. Patients with an organ allograft or other history of immune compromise
  4. Prior exposure to mTOR inhibitors
  5. Hypersensitivity to rapamycin or other similar compounds
  6. Prior treatment with any investigational drug within the preceding 4 weeks
  7. Chronic treatment with systemic steroids or another immunosuppressive agent
  8. A known history of HIV seropositivity
  9. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
  10. Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin defined as 1 mg a day).
  11. Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration)
  12. Patients with a pre-existing peripheral neuropathy > grade 1
  13. Patients taking medications metabolized by the CYP3A4 subfamily will not be included in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00499603

Locations
United States, Texas
U.T. M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Novartis
Investigators
Principal Investigator: Ana Gonzalez-Angulo, M.D. M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00499603     History of Changes
Other Study ID Numbers: 2006-0790
Study First Received: July 9, 2007
Results First Received: April 1, 2013
Last Updated: August 27, 2013
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:
Breast Cancer
ER negative
PR negative
HER2neu negative
Tumor Triple Negative Receptors
Paclitaxel
Taxol
RAD001
FEC
5-Fluorouracil
5-FU
Adrucil
Efudex
Epirubicin
Cyclophosphamide

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Cyclophosphamide
Epirubicin
Fluorouracil
Sirolimus
Everolimus
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on October 19, 2014